Contineum Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Contineum Therapeutics, Inc. (CTNM) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-07-30
- Contineum Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$611.00K.
- Contineum Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $1.62M.
- Contineum Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $2.50M, a 535.53% increase year-over-year.
- Contineum Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $1.17M.
- Contineum Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $3.40M.
- Contineum Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$887.00K, a 169.46% decline from fiscal 2023.
- Contineum Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $1.28M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$611.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.00M 10-Q · filed 2026-07-30 | $3.51M derived: sum of 3 quarters · filed 2026-07-30 | $4.67M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $1.62M 10-Q · filed 2026-05-05 | $4.12M derived: sum of 2 quarters · filed 2026-05-05 | $5.29M derived: sum of 3 quarters · filed 2026-05-05 | $5.21M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.67M derived: sum of 2 quarters · filed 2026-03-05 | $3.60M derived: sum of 3 quarters · filed 2026-07-30 | $3.40M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.09M derived: sum of 2 quarters · filed 2026-07-30 | $892.00K 10-Q · filed 2025-10-30 | $1.29M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$273.00K 10-Q · filed 2026-07-30 | $121.00K derived: sum of 3 quarters · filed 2026-07-30 | -$314.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$203.00K 10-Q · filed 2026-05-05 | $191.00K derived: sum of 2 quarters · filed 2026-05-05 | -$244.00K derived: sum of 3 quarters · filed 2026-05-05 | -$377.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $394.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$41.00K derived: sum of 2 quarters · filed 2026-03-05 | -$174.00K derived: sum of 3 quarters · filed 2026-03-05 | -$887.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | -$435.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$568.00K derived: sum of 2 quarters · filed 2025-10-30 | -$1.28M 10-Q · filed 2025-10-30 | -$1.26M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | -$133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$846.00K 10-Q · filed 2025-08-05 | -$822.00K derived: sum of 3 quarters · filed 2025-08-05 | $417.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$713.00K 10-Q · filed 2025-05-14 | -$689.00K derived: sum of 2 quarters · filed 2025-05-14 | $550.00K derived: sum of 3 quarters · filed 2025-05-14 | $504.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.26M derived: sum of 2 quarters · filed 2025-03-06 | $1.22M derived: sum of 3 quarters · filed 2025-03-06 | $1.28M 10-K · filed 2025-03-06 |
| 2023-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.19M derived: sum of 2 quarters · filed 2024-11-06 | $1.25M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $14.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $60.00K 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |